Qiagen ipsogen BCR-ABL1 Mbcr RGQ RT-PCR Manual página 51

7. Hughes, T. et al. (2006) Monitoring CML patients responding to treatment
with tyrosine kinase inhibitors: review and recommendations for
harmonizing current methodology for detecting BCR-ABL transcripts and
kinase domain mutations and for expressing results. Blood 108, 28.
8. White, H.E. et al. (2010) Establishment of the first World Health
Organization International Genetic Reference Panel for quantitation of
BCR-ABL mRNA. Blood 116, e111.
Referencias no citadas en el texto pero que pueden resultar de utilidad:
Baccarani, M. et al. (2006) Evolving concepts in the management of chronic
myeloid leukemia: recommendations from an expert panel on behalf of the
European LeukemiaNet. Blood 108, 1809.
Beillard E. et al. (2003) Evaluation of candidate control genes for diagnosis
and residual disease detection in leukemic patients using 'real-time' quantitative
reverse-transcriptase polymerase chain reaction (RQ-PCR)—a Europe against
cancer program. Leukemia 17, 2474.
Gabert J. et al. (2003) Standardization and quality control studies of 'real-time'
quantitative reverse transcriptase polymerase chain reaction of fusion gene
transcripts for residual disease detection in leukemia—a Europe Against Cancer
program. Leukemia 17, 2318.
van der Velden, V.H., Hochhaus, A., Cazzaniga, G., Szczepanski, T., Gabert
J., and van Dongen, J.J. (2003) Detection of minimal residual disease in
hematologic malignancies by real-time quantitative PCR: principles, approaches,
and laboratory aspects. Leukemia 17, 1013.
Manual del kit ipsogen BCR-ABL1 Mbcr RGQ RT-PCR 12/2014 51